The SOS1:KRAS inhibitor BI-3046, developed by Boehringer Ingelheim, has been evaluated in vivo in NSCLC and CRC PDX models specifically in combination with trametinib (MEK inhibitor). Here, KRAS is linked to non-small cell lung carcinoma.